Banque Pictet & Cie SA Lowers Stake in BioNTech SE (NASDAQ:BNTX)

Banque Pictet & Cie SA cut its stake in BioNTech SE (NASDAQ:BNTX) by 5.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,070 shares of the company’s stock after selling 110 shares during the quarter. Banque Pictet & Cie SA’s holdings in BioNTech were worth $236,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Baillie Gifford & Co. lifted its stake in BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after buying an additional 31,773 shares in the last quarter. FMR LLC increased its holdings in shares of BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after buying an additional 5,598,190 shares during the last quarter. Fred Alger Management LLC acquired a new stake in shares of BioNTech during the 3rd quarter worth approximately $59,485,000. DekaBank Deutsche Girozentrale increased its holdings in shares of BioNTech by 12.6% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock worth $56,886,000 after buying an additional 53,800 shares during the last quarter. Finally, abrdn plc increased its holdings in shares of BioNTech by 70.7% during the 4th quarter. abrdn plc now owns 385,668 shares of the company’s stock worth $43,947,000 after buying an additional 159,676 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the stock from $90.00 to $137.00 in a report on Friday, November 8th. Wells Fargo & Company started coverage on shares of BioNTech in a report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price for the company. TD Cowen dropped their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. Truist Financial started coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 target price for the company. Finally, Berenberg Bank started coverage on shares of BioNTech in a report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 target price for the company. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $142.72.

BioNTech Price Performance

BioNTech stock opened at $119.83 on Friday. The stock has a market cap of $28.73 billion, a P/E ratio of -57.06 and a beta of 0.17. The company has a fifty day simple moving average of $117.22 and a 200-day simple moving average of $109.45. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.